Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1762MR)

This product GTTS-WQ1762MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1762MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8623MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ11044MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ4750MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ15481MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ15547MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ4919MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ8405MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ12458MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW